Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582711 · ClinicalTrials.gov registry record · Phase 3
Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
A Phase 3 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,002
- Enrollment target
NCT01582711: Completed Phase 3 study, sponsored by Centers for Disease Control and Prevention.
NCT01582711 is a Phase 3 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 1,002 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582711, a Phase 3 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,002 participants
- Enrollment target
Study Summary
The study is an open label, multicenter, randomized (three arms: DOT (standard control), SAT, SAT with SMS reminders) controlled clinical trial. The trial is conducted in patients diagnosed with latent tuberculosis infection (LTBI) who are recommended for treatment. The primary objective is to evaluate adherence to a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) given by directly observed therapy (DOT) compared to self-administered therapy (SAT). The secondary objectives: * To compare the treatment completion rates between participants randomized to SAT without reminders versus SAT with weekly SMS reminders * To evaluate the timing of doses and patterns of adherence to once weekly RPT/INH among participants who complete treatment and those who discontinue therapy prior to completion. * To determine the availability and acceptability of using SMS reminders among all patients consenting to participate in the study. * To determine the toxicity and tolerability by comparing the rates of any drug-related grade 3 or 4 adverse events or death between the DOT arm and the SAT arms (both combined and individually) * To compare the frequency, timing, and causes for failure to complete treatment between the DOT arm and the SAT arms * To collect patient-specific cost data related to the 3 treatment arms * To describe the pattern of antituberculosis drug resistance among Mycobacterium tuberculosis strains cultured from participants who develop active TB.
Primary Outcome
To compare the treatment completion rates between participants randomized to DOT vs SAT without reminders and DOT versus SAT with weekly SMS reminders. Treatment completion is defined as taking at least 90% of the doses (11/12 doses of each drug) within 16 weeks of treatment initiation.
Interventions
- BEHAVIORAL Self Administered Therapy (SAT)
- BEHAVIORAL SMS reminders
- DRUG isoniazid and rifapentine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,002 participants |
| Start Date | 2012-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
What the finished NCT01582711 record still lists
NCT01582711 is an interventional study that assigns participants to a tested intervention. Its 1,002 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 3 interventions - of which Self Administered Therapy (SAT) is the first listed.
NCT01582711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582711 about?
NCT01582711 is a clinical study titled "Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT". The study is an open label, multicenter, randomized (three arms: DOT (standard control), SAT, SAT with SMS reminders) controlled clinical trial. The trial is conducted in patients diagnosed with latent tuberculosis infection (LTBI) who are recommended for treatment. The primary objective is to evalu...
What is the current status of trial NCT01582711?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,002 participants. The study started on 2012-09. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01582711?
The interventions under investigation include: Self Administered Therapy (SAT) (BEHAVIORAL), SMS reminders (BEHAVIORAL), isoniazid and rifapentine (DRUG).
Who is sponsoring clinical trial NCT01582711?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01582711's enrollment target sits among peer trials
1,002 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia